At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.
Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.
* This video was published in January 2013. The information contained in this video speaks only as of January 2013, and TNI BioTech, Inc. has, and accepts, no responsibility or duty to update any such information and reserves the right to add to, remove or amend any information contained in this video. This video may contain projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon expectations as of the date of this video and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in our most recent Securities and Exchange Commission filings. Although we may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.
Spleen mononuclear cells of BALB/C mice and YAC-1 cells were used in this experiment.
Leucine enkephalin or methionine enkephalin at time 0 was added to cell cultures and the amount of the enzyme lactate dehydrogenase released from lysed target cells was determined 22 hours after incubation. There were on average 41% (5% to 60.7%) and 63% (46.8% to 78%) enhancements of natural killer activity in the presence of leucine enkephalin (1 x 10(-11)-1 x 10(-3) mg/ml) and methionine enkephalin (1 x 10(-15)-1 x 10(-3) mg/ml) respectively. The results showed that opioid peptides can modify NK cell function.